BCM
PVLA

Bridgeway Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Bridgeway Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,456
Closed -$114K – 1459
2023
Q1 		$114K Hold
1,456
– – ﹤0.01% 1212
2022
Q4 		$121K Hold
1,456
– – ﹤0.01% 1191
2022
Q3 		$134K Sell
1,456
-1,208
-45% -$156K ﹤0.01% 1220
2022
Q2 		$398K Buy
+2,664
New +$486K 0.01% 929

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bridgeway Capital Management's PVLA Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Palvella Therapeutics (PVLA) in Q2 2023, closing a stake of 1,456 shares — an estimated $114K sold.

Bridgeway Capital Management first reported a position in PVLA in Q2 2022 and held it in 4 quarters. The position peaked at $398K in Q2 2022. 49 funds tracked by Wall St. Rank hold PVLA as of Q2 2023.

  • Bridgeway Capital Management reported no remaining Palvella Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 1,456 Palvella Therapeutics shares in Q2 2023, an estimated $114K.
  • Bridgeway Capital Management first reported a position in Palvella Therapeutics in Q2 2022 and held it in 4 quarters.
  • Bridgeway Capital Management's Palvella Therapeutics position peaked at $398K in Q2 2022.
  • 49 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.